DiagnoCure announces results of its Annual and Special Meeting of shareholders

MONTREAL, May 19, 2016 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) (OTC Pink: DGCRF) (the "Corporation") today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated April 14, 2016 and put forth for vote during the annual and special meeting of the shareholders (the "Meeting") held today in Montreal.

Shareholders holding collectively 31.2% of all issued and outstanding shares of DiagnoCure were present or represented by proxy at the Meeting. Shareholders re-elected Dr. Louise Proulx, Dr. Jacques Simoneau, and Dr. Vincent R. Zurawski as directors of the Corporation and the specifics of the vote are as follows:



Shares For

For (%)

Shares Withheld

Withheld (%)


Louise Proulx






Jacques Simoneau






Vincent R. Zurawski







Shareholders also reappointed Ernst & Young as auditor of the Corporation and the result is as follows:


Shares For

For (%)

Shares Withheld

Withheld (%)


Auditor appointment







The shareholders also approved the special resolutions related to both the voluntary liquidation and dissolution (the "Liquidation") and the change in corporate name (the "Name Change"). Each of these two resolutions to be approved required the favorable vote of 66 2/3% of the votes cast by shareholders of DiagnoCure. The special resolution approving the Liquidation was approved by x% of the votes cast by the shareholders. The special resolution approving the Name Change was approved by x% of the votes cast by the shareholders.

Delisting from the TSX

DiagnoCure expects that the delisting of the shares from the Toronto Stock Exchange will happen at the closing of the business on June 6, 2016 and that the liquidator, PricewaterhouseCoopers inc., will take over the same day. Effective the same day, DiagnoCure's shares will also cease to be quoted on the OTC Pink.

About DiagnoCure

DiagnoCure (TSX: CUR; OTC Pink: DGCRF) is a life sciences corporation that develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. Previstageâ GCC and the Corporation new multimarker prostate cancer test (PCP) are currently available for licensing. For more information, please visit www.diagnocure.com.

Forward‐looking statements

This release may contain forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forward‐looking statements are based on expectations and assumptions and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forward‐looking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PCP Risk Score are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.


SOURCE DiagnoCure inc.

For further information: DiagnoCure Inc., Danielle Allard, Sr. Director, Corporate Affairs, (418) 527-6100, communications@diagnocure.com


Organization Profile

DiagnoCure inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890